Anakinra
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Anakinra: From Autoinflammatory Diseases to Extracutaneous Mastocytoma
One-Sentence Summary
Anakinra (Kineret) is a recombinant human IL-1 receptor antagonist (IL-1Ra) used for rheumatoid arthritis and IL-1-mediated autoinflammatory diseases; its original indication is not formally recorded in this Evidence Pack. The TxGNN model predicts it may be effective for Extracutaneous Mastocytoma, however, there are currently 0 clinical trials and 0 publications directly supporting this direction — making this a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Evidence Pack (known use: rheumatoid arthritis, autoinflammatory diseases) |
| Predicted New Indication | Extracutaneous Mastocytoma |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not captured in this Evidence Pack. Based on established pharmacology, Anakinra is a recombinant human IL-1 receptor antagonist that competitively blocks the binding of both IL-1α and IL-1β to their shared receptor IL-1R1. By preventing IL-1 receptor engagement, Anakinra suppresses the downstream NF-κB signaling cascade and the release of secondary inflammatory mediators. It was developed specifically for diseases where IL-1β-driven inflammation is central to pathogenesis.
Extracutaneous mastocytoma is a rare neoplastic condition characterised by clonal mast cell accumulation in extracutaneous organs. Mast cells are capable of secreting IL-1β upon activation, and the theoretical rationale is that IL-1Ra blockade might dampen the local inflammatory microenvironment surrounding neoplastic mast cell infiltrates.
However, the biological link between IL-1 signaling and the oncogenic driver of extracutaneous mastocytoma (typically activating KIT mutations, e.g. D816V) has not been established in the literature. Unlike inflammasome-driven autoinflammatory diseases — where Anakinra’s efficacy is well-documented — this is primarily a mast cell neoplasm rather than an IL-1-dependent inflammatory syndrome. The TxGNN prediction reflects network proximity in the knowledge graph and should be treated as a mechanistic hypothesis requiring experimental validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Anakinra is currently not marketed in Canada. No Drug Identification Numbers (DINs) are on record in this Evidence Pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported solely by TxGNN network-based inference (Evidence Level L5), with no clinical trials, observational studies, or publications directly evaluating Anakinra in extracutaneous mastocytoma. The mechanistic link via IL-1β secretion from neoplastic mast cells is biologically conceivable but entirely unvalidated, and the dominant oncogenic mechanism (KIT mutation) is independent of the IL-1 pathway.
To proceed, the following is needed:
- Preclinical studies (in vitro / in vivo) measuring IL-1β levels in extracutaneous mastocytoma tissue and assessing IL-1Ra response in relevant mast cell neoplasm models
- Literature review clarifying whether IL-1 signalling plays any functional role in KIT-mutant mast cell proliferation or survival
- Full MOA documentation retrieved via DrugBank API to confirm Anakinra’s classification and target profile
- Health Canada / TFDA package insert review for complete warnings, contraindications, and drug interaction profile
- Exploration of whether any case reports describe IL-1 inhibition in systemic mastocytosis variants (noting that aggressive systemic mastocytosis at rank 4 has marginal indirect case report evidence via Schnitzler syndrome)
Disclaimer: The results of this report are for research reference only and do not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.